As mentioned earlier, decreased expression of ST6Gal1 in prostate cancer models results in diminished activation of a PI3K/AKT/GSK-3β signaling axis, leading to diminished β-catenin (Wei et al., 2016). This evidence concerns the gene ST6GAL1 and prostate carcinoma.